Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Trial Profile

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Talazoparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TALAPRO-2
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Jan 2024 Results of exploratory biomarker analyses assessing HRR gene subgroups and potential associations with secondary efficacy endpoints in pts with HRRm tumors, presented at the 2024 Genitourinary Cancers Symposium
    • 08 Jan 2024 According to a Pfizer media release, based on this study, the European Commission (EC) has approved talazoparib in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. This approval in all 27 EU member states plus Iceland, Liechtenstein, and Norway.
    • 01 Jan 2024 Results for radiographic progression-free survival and safety, published in the Nature Medicine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top